Phyto science
It is my pleasure to welcome you to Canna Therapeutic.
The company was founded in October 2016 in Copenhagen. Canna Therapeutic is a biotechnology and phyto-science company that employee approximately 25 people. We are specializing innovative treatments using EU-GMP pharma-grade medical cannabis and phyto-science.
The company is developing a portfolio of API’s from various cannabis compounds as well as drug candidates, originating from the cannabis plant. We also supply dried products to selected markets in EU-GMP pharmaceutical quality.
Behind the scene there is a group of dedicated and highly motivated people with many years of experience in biotech, analytical chemistry, cannabis industry, agriculture, innovation and quality assurance.
Steen Pontoppidan,
Chief Executive Officer and Founder
Innovation
We are a professional and dedicated team with experts from all over the world. We started the company to improve the quality of life for our patients. We have many partners and alliances that help us explore and exploit the potential of the pharmaceutical cannabis industry.
At Canna Therapeutic, we believe that gathering all the relevant expertise is the key to develop a drug and bring it to the market.
Our business model is based on collaboration and our partnerships illustrate that belief. Business development is an integral part of our business strategy and is decisive to support our dynamic growth.
We welcome opportunities for alliances or partnerships with business partners who could bring our drug candidates to the market and allow patients to access our innovative therapeutic solutions.
We are open to different types of alliances that could enhance the project value and be beneficial for both partners. Regarding our BD & L strategy and the business objectives of our partners, we are prone to design an adapted collaborative approach for a mutually beneficial agreement.
If you are interested in pursuing a collaboration opportunity or investment with Canna Therapeutic, please feel free to contact us.
The true challenge is to stay on track of the right combination of exploration and exploitation and as such being an ambidextrous organization.
